New heat-activated gel could boost liver cancer therapy

NCT ID NCT07356531

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new gel that hardens at body temperature to block blood flow to liver tumors during chemoembolization. About 216 adults with liver cancer will receive either the new gel or standard gelatin sponge particles. The goal is to see if the new gel better controls tumor growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Affiliated Cancer Hospital of Guangxi Medical University

    RECRUITING

    Nanning, Guangxi, 530012, China

  • Anhui Provincial Hospital

    RECRUITING

    Hefei, Anhui, 230002, China

  • Anyang Tumor Hospital

    RECRUITING

    Anyang, Henan, 455001, China

  • First Affiliated Hospital of Gannan Medical University

    RECRUITING

    Ganzhou, Jiangxi, 341099, China

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, Henan, 450000, China

  • Jilin Guowen Hospital

    RECRUITING

    Gongzhuling, Jilin, 130028, China

  • Lishui Central Hospital

    RECRUITING

    Lishui, Zhejiang, 323020, China

  • Peking University First Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100034, China

  • Shanxi Bethune Hospital

    RECRUITING

    Taiyuan, Shanxi, '030032, China

  • The Affiliated Cancer Hospital of Guizhou Medical University

    RECRUITING

    Guiyang, Guizhou, 550008, China

  • The First Affiliated Hospital of Henan University of Science & Technology

    RECRUITING

    Luoyang, Henan, 471023, China

  • The First Affiliated Hospital of Wenzhou Medical University

    RECRUITING

    Wenzhou, Zhejiang, 325000, China

  • The Fourth Hospital of Hebei Medical University (Hebei Provincial Cancer Hospital)

    RECRUITING

    Shijiazhuang, Hebei, '050010, China

  • The Second Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, Jiangxi, 330008, China

  • Yichang Central People's Hospital

    RECRUITING

    Yichang, Hubei, 443008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.